Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial by Robert A Fowler et al.
TRIALS
Fowler et al. Trials 2014, 15:502
http://www.trialsjournal.com/content/15/1/502STUDY PROTOCOL Open AccessEconomic evaluation of the prophylaxis for
thromboembolism in critical care trial (E-PROTECT):
study protocol for a randomized controlled trial
Robert A Fowler1*, Nicole Mittmann2, William H Geerts3, Diane Heels-Ansdell4, Michael K Gould5, Gordon Guyatt4,
Murray Krahn6, Simon Finfer7, Ruxandra Pinto1, Brian Chan8, Orges Ormanidhi9, Yaseen Arabi10, Ismael Qushmaq11,
Marcelo G Rocha12, Peter Dodek13,14, Lauralyn McIntyre15, Richard Hall16, Niall D Ferguson17,18, Sangeeta Mehta19,
John C Marshall20, Christopher James Doig21, John Muscedere22, Michael J Jacka23, James R Klinger24,
Nicholas Vlahakis25, Neil Orford26,27, Ian Seppelt28, Yoanna K Skrobik29, Sachin Sud30, John F Cade31, Jamie Cooper32,
Deborah Cook33 and On behalf of the Canadian Critical Care Trials Group and the Australia and New Zealand Intensive
Care Society Clinical Trials GroupAbstract
Background: Venous thromboembolism (VTE) is a common complication of critical illness with important clinical
consequences. The Prophylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) is a multicenter, blinded,
randomized controlled trial comparing the effectiveness of the two most common pharmocoprevention strategies,
unfractionated heparin (UFH) and low molecular weight heparin (LMWH) dalteparin, in medical-surgical patients in
the intensive care unit (ICU). E-PROTECT is a prospective and concurrent economic evaluation of the PROTECT trial.
Methods/Design: The primary objective of E-PROTECT is to identify and quantify the total (direct and indirect,
variable and fixed) costs associated with the management of critically ill patients participating in the PROTECT trial,
and, to combine costs and outcome results to determine the incremental cost-effectiveness of LMWH versus UFH,
from the acute healthcare system perspective, over a data-rich time horizon of ICU admission and hospital admission.
We derive baseline characteristics and probabilities of in-ICU and in-hospital events from all enrolled patients.
Total costs are derived from centers, proportional to the numbers of patients enrolled in each country. Direct costs
include medication, physician and other personnel costs, diagnostic radiology and laboratory testing, operative and
non-operative procedures, costs associated with bleeding, transfusions and treatment-related complications. Indirect
costs include ICU and hospital ward overhead costs. Outcomes are the ratio of incremental costs per incremental
effects of LMWH versus UFH during hospitalization; incremental cost to prevent a thrombosis at any site (primary
outcome); incremental cost to prevent a pulmonary embolism, deep vein thrombosis, major bleeding event or episode
of heparin-induced thrombocytopenia (secondary outcomes) and incremental cost per life-year gained (tertiary
outcome). Pre-specified subgroups and sensitivity analyses will be performed and confidence intervals for the estimates
of incremental cost-effectiveness will be obtained using bootstrapping.
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Discussion: This economic evaluation employs a prospective costing methodology concurrent with a randomized
controlled blinded clinical trial, with a pre-specified analytic plan, outcome measures, subgroup and sensitivity analyses.
This economic evaluation has received only peer-reviewed funding and funders will not play a role in the generation,
analysis or decision to submit the manuscripts for publication.
Trial registration: Clinicaltrials.gov Identifier: NCT00182143. Date of registration: 10 September 2005.
Keywords: Economic, Cost-effectiveness, Venous, Thromboembolism, PROTECT, Unfractionated, Heparin, Low
molecular weight, Intensive, CriticalBackground
Venous thromboembolism (VTE) is a common compli-
cation of critical illness and has important clinical conse-
quences, including deep vein thrombosis (DVT), pulmonary
embolism (PE), increased length of stay in the intensive
care unit (ICU) and hospital and death [1-3]. Although
DVT has potentially serious consequences, it is often
unrecognized in the ICU as the clinical examination for
DVT lacks sensitivity and specificity [4]. Further, routine
ultrasound screening for DVT is not a cost-effective diag-
nostic strategy in practice [5]. Thus, thromboprophylaxis
is the most appropriate mechanism to prevent VTE and
its complications among critically ill patients.
We have previously documented that most economic
evaluations of VTE strategies are designed after the results
of the trial are known, and are funded by the manufacturers
of the agents compared [6]. This introduces the opportun-
ity for biased design and interpretation of economic evalu-
ations. Therefore, we designed the economic evaluation
(E-PROTECT) of a multicenter randomized, blinded con-
trolled trial of 3,746 patients comparing the effectiveness
of unfractionated heparin (UFH) and low molecular
weight heparin (LMWH) (dalteparin) [7]. The primary
objective of E-PROTECT is to identify and quantify the
total (direct and indirect, variable and fixed) costs asso-
ciated with the management of critically ill patients
participating in the PROTECT trial, and to combine costs
and outcome results to determine the incremental cost-
effectiveness of LMWH versus UFH, from the acute
healthcare system perspective, over a data-rich time
horizon of the ICU admission and hospital admission.
Methods/Design
E-PROTECT background studies and methodologies
The PROTECT trial
The objective of the Canadian Institutes of Health Research
(CIHR)-funded PROTECT trial [7,8] was to evaluate
LMWH versus UFH on the primary outcome of the inci-
dence of proximal leg DVT diagnosed by compression
ultrasound, with secondary outcomes of PE, venous
thrombosis at any site, bleeding and heparin-induced
thrombocytopenia (HIT). The study design was a ran-
domized, stratified, concealed double-blind multicentertrial with enrolment throughout Canada, Australia, the
United States, Saudi Arabia, the United Kingdom and
Brazil. The PROTECT trial enrolled 3,746 critically ill
patients between May 2006 and June 2010 according to
previously published eligibility criteria [7,8]. A central
computerized web-based or phone-in randomization sys-
tem ensured concealed randomization of patients to either
dalteparin 5,000 international units (IU) daily or UFH
5,000 IU twice daily subcutaneously for the ICU stay. Only
the research pharmacist at each participating centre was
aware of the allocation. Bilateral proximal leg compression
ultrasounds were performed within 48 hours of ICU ad-
mission, twice weekly and on DVT suspicion. A prede-
fined algorithm was used to diagnose PE; bleeding, HIT,
other thrombosis and complications were identified using
a priori definitions and procedures. The PROTECT publi-
cation itself provides complete study data [7].
The E-PROTECT pilot study
To first determine the feasibility of obtaining patient-
specific line-item costing (for each aspect of care delivery),
we conducted a pilot study between 2006 and 2007
involving six hospitals in Canada, the United States and
Australia [9]. However, we discovered that in both
privately funded and publically funded institutions, the
variability around patient costing was substantial and
that line-item costs were not routinely available. Many
costs were ‘rolled up’ into summary cost measures, and
subsequently, this methodology would not allow for a
linkage of costs and clinical events to be measured as part
of the PROTECT trial case report form. Therefore, we
designed a more appropriate cost gathering methodology
to capture hospital-specific line-item costs according to
important variables that we anticipated will drive costs
and possible cost-effectiveness (Additional file 1).
In order to determine such cost drivers, we performed
a systematic review of economic analyses of thrombo-
prophylaxis strategies in hospitalized patients to identify
variables that we anticipate will drive costs and possible
cost-effectiveness in E-PROTECT, and to determine poten-
tial ranges for willingness-to-pay to avoid DVT and PE
[6]. From 5,180 potentially relevant studies, 39 met the
eligibility criteria from which we extracted data on study
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identifying variables likely to be influential in E-PROTECT,
we found that LMWHs appear to be the most economically
attractive drugs for VTE prevention in acutely ill hospital-
ized patients, whereas newer agents may be more econom-
ically attractive in patients receiving joint replacement
surgeries. However, the manufacturer of the new agent sup-
ported approximately two-thirds of evaluations and such
drugs were likely to be reported as economically favorable.
Incremental cost-effectiveness ratios to prevent VTE events
ranged from a dominance of LMWH to under $5,000 per
VTE event avoided [6].E-PROTECT methods
E-PROTECT design and economic assumptions
We designed E-PROTECT before the results of the
PROTECT trial were known. Study funding was from
peer-reviewed sources and none of the funders played a
role in the generation, analysis or decision to submit the
economic evaluation for publication. We developed our
analysis according to established guidelines [10-14]. Also,
we used an acute healthcare system perspective (during
the period of hospitalization) to encompass all in-patient
direct medical and hospital costs, including physician and
other personnel costs. Our preliminary analytic plan was
pre-specified with public study funders (Heart and Stroke
Foundation, Ontario, Canada) as part of the economic
evaluation of the PROTECT trial protocol prior to com-
pletion of the trial and unblinding of the economic conse-
quences of clinical data.E-PROTECT patients, outcomes and effects
No patients were lost to follow-up. Although the PROTECT
trial considered both intention-to-treat and on-treatment
analyses, primary outcomes were based on adherence to
the intention-to-treat principle and will form the clinical
event estimates of the economic analyses. We recorded
the frequency of DVT, PE, major bleeding and HIT among
all patients to measure the primary clinical incremental
effect of the difference in any VTE (all limb DVT, PE and
non-limb thromboses), and secondary clinical incremental
effects of episodes of PE, DVT, major bleeding and HIT.
The PROTECT trial was designed and powered to evalu-
ate differences in the rate of thrombotic events between
two pharmacologic thromboprophylaxis strategies, not
differences in life expectancy; accordingly, incremental
differences in life years are not primary outcomes in
this economic evaluation. All measures of clinical events,
medications administered, laboratory and radiology test-
ing, complications, blood product transfusions, proce-
dures and surgeries and duration of ventilation, ICU and
hospital stay were recorded alongside the PROTECT trial
as part of the study case report form [7,8].E-PROTECT costs
Total, direct and indirect costs
Total costs for patients in the PROTECT trial comprise
direct and indirect costs [15]. To determine which cost
to include, we performed a systematic review of the VTE
cost-effectiveness literature [6] for hospitalized patients,
and reviewed evidence underlying the relative importance
among the E-PROTECT Steering Committee, before decid-
ing upon final cost variables. Direct costs are attributable to
medications, transfusions, laboratory or radiology tests or
procedures or personnel directly associated with specific
components of patient care. Such costs can usually be
determined on an item-by-item, procedure-by-procedure
basis. Indirect costs are those for services or procedures
that often benefit more than one patient at a time and
their precise benefits to specific patients are often difficult
to trace, such as maintenance of equipment and infra-
structure. A large proportion of such indirect costs com-
prise the ‘overhead’ in operating an ICU, laboratory or
pharmacy, for example [10,15,16]. These costs can be
fixed (roughly the same amount on a recurring basis), or
variable (fluctuating depending upon patient circum-
stances and course). E-PROTECT measured both direct
and estimated indirect costs at study sites.
Direct costs from participating sites
Direct and indirect costs were sought from 23 of 67
hospitals and five of six countries participating in the
PROTECT trial (12 hospitals in Canada; five hospitals
in Australia; three hospitals in the United States; two
hospitals in Saudi Arabia; one hospital in Brazil). Sites
will be invited to participate in the costing component
of the economic evaluation to reflect overall propor-
tions of patients enrolled in the PROTECT trial among
all participating countries. Direct costs will be divided
among the following categories: 1) study-related drugs
(unfractionated heparin, dalteparin, enoxaparin, tinza-
parin, other low molecular weight heparins, protamine,
Desmopressin (DDAVP), aprotinin, aminocaproic acid,
danaparoid, lepirudin, argatroban, fondaparinux, activated
Factor VII, acetyl salicylic acid (ASA), clopidogrel, a repre-
sentative proton-pump inhibitor (pantoprazole), vitamin
K, warfarin and epinephrine for injection or infusion);
2) laboratory testing (complete blood count, electrolytes,
creatinine, blood urea nitrogen, arterial blood gas, partial
thromboplastin and prothrombin time, anti-Xa level,
enzyme-linked immunosorbent assay (ELISA) and sero-
tonin release HIT assay); 3) personnel (including per
diem most responsible physician and per consultation
physician charges over the course of an ICU and hospital
admission, nursing, pharmacist, respiratory therapist, phys-
ical therapist, social work and ICU administrative and/
or clerical staffing hourly wage range); 4) radiology (uni-
lateral and bilateral leg compression ultrasonography
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tomography (CT) scan of the chest with an angiogram
(pulmonary embolism protocol), CT scan of the abdomen,
pelvis, and head, pulmonary angiogram and ventilation-
perfusion scan); 5) procedural costs (electrocardiogram,
central venous catheter material costs, inferior vena cava
filter material and insertion and removal costs, naso- or
oro-gastric tube, procedure costs for gastroscopy, colonos-
copy, bronchoscopy, and angiography with embolization
and intermittent and continuous renal replacement ther-
apy); and, 6) operative costs for laparotomy (including the
surgeon and surgical assistant, anesthesiology and nursing
personnel costs).
Operative and bedside surgical procedures were classi-
fied according to procedure and body site (head and neck,
cardiac, vascular, thoracic, gastrointestinal, orthopedic,
genitourinary, plastic, neurosurgical or other), by two
independent adjudicators, blinded to treatment allocation,
with separate attribution as to whether the procedure was
conceivably precipitated or related to the study drug
(bleeding or thromboses). Disagreements were resolved by
consensus or a third reviewer. Rates of all surgeries and
study drug-related surgeries will be compared for each
study group and those we believe to be possibly related to
the study drug will be included in the cost analysis.
Direct costs associated with heparin-induced thrombocytopenia
As episodes of HIT with thrombosis (HITT) and without
thrombosis involve complex and expensive investigation
and treatment, some authors previously performed a
single-center micro-costing study in one PROTECT trial
center. They aimed to estimate the total average attribut-
able costs of an episode of HIT (and HITT including
arterial and venous thromboses), as well as associated
HIT-safe anticoagulants, associated bleeding and special-
ized HIT diagnostic testing. The details of the micro-
costing study are published elsewhere [17] but included
diagnosis, investigation, treatment and administration
costs. However, for E-PROTECT, we will capture costs
and measures of resource use for complications such as
bleeding, HIT and HITT as part of the PROTECT case
report and centre-specific E-PROTECT costs, and will not
assign additional HIT or bleeding-specific costs in order
to avoid double counting. Bleeding and blood product
transfusion services costs (per unit of red blood cells, fro-
zen plasma and thawing, cryoprecipitate, cross matching
and platelets and associated laboratory testing of blood
type and screen) were derived from a Canadian national
transfusion resource, education and costing exercise [18].
Prophylactic and therapeutic anticoagulation outside the ICU
Ward-based prophylactic and therapeutic anticoagulation
was not directly measured; therefore, we will make the
following assumptions:1. If no therapeutic anticoagulation was used in last
two days in ICU, we will assume UFH prophylaxis
will be used for the entire ward stay;
2. If warfarin was used in last two days in ICU, we will
assume that warfarin will be used for entire ward stay;
3. If treatment doses of LMWH were used in last two
days in ICU, we will assume that treatment with
LMWH will continue for five days on the ward,
followed by warfarin for the remainder of the
hospital stay;
4. If treatment doses of UFH were used in last two
days in ICU, we will assume that treatment with
UFH occurs for five days on the ward, followed by
warfarin for the remainder of the hospital stay;
5. If treatment doses of danaparoid or other HIT-safe
anticoagulants were used in last two days in ICU, we
will assume that treatment with danaparoid or other
HIT-safe anticoagulants occurs for five days on the
ward, followed by warfarin for the remainder of the
hospital stay.Indirect costs - ICU and ward care
We will measure institution-specific estimates of indir-
ect (overhead) costs per day of care in the center’s
highest acuity ICU (capable of providing ventilation
and hemodynamic support), and for patients receiving
care on standard medical and surgical wards. From the
E-PROTECT pilot, we found that each institution deter-
mined this cost per day in a unique fashion, but generally
comprised components of non-physician personnel cost,
equipment maintenance, some diagnostic testing and ICU
and other ward overhead infrastructure costs [9]. This
rolled-up indirect per day cost will be determined to esti-
mate the difference between the total of individual direct
costs relevant for patients in the PROTECT trial (above),
and the total daily costs of care that may reflect additional
and indirect costs which are important in determining
total costs, but are difficult to capture as single variables.
Mean institutional costs of ICU care typically represent
very high costs on the first day, and substantially lower
(one-quarter) costs after the second day [16], with a fur-
ther decrease after discharge to a ward bed. Using our
hospital estimates of indirect costs in ICUs and on the
ward, and in accordance with prior literature, we will
apply a ratio of 1 (hospital ward):2.5 (ICU day two on-
wards):4 (ICU day one) [16,19-21]. Most daily costs of
care in ICUs are fixed, not variable, and prior work has
demonstrated minimal direct-variable cost differences due
to ventilation status [16]. Because of this and because the
vast majority of ICU days represent days patients received
mechanical ventilation, we will apply a small incremental
(between 3 and 5%) daily indirect cost due to this ad-
vanced life support [16].
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We measured all costs at each site using a costing opera-
tions manual outlining a standardized multistep process
(Additional file 1). Between 2007 and 2011, the principal
investigator and a research assistant contacted the site
principal investigator and research coordinator at each
participating center with the list of variable costs required,
who then subsequently contacted the most appropriate
individual in each hospital’s accounting, human resources,
pharmacy, radiology and laboratory services and blood
bank. Standard definitions (per unit of measurement or
time, and so on) were created and explained and hospital-
specific costs requested for each variable. Where costs
were influenced by extra-hospital jurisdictions (such as
jurisdictional payer physician costs, unionized employees
and reference laboratory costs), these were recorded. In all
cases, costs were requested but if only charges were
known, then we converted to costs by the institution’s
cost-to-charge estimate for that item. Both professional
(performance and/or interpretation) and technical costs
were recorded for procedures when applicable. We under-
took an iterative series of communications until no further
data could be gleaned. All data are without patient identi-
fiers and are be maintained in password-protected and
encrypted laptop or desktop, in locked offices.
Exploring cost variability among sites
To explore variability among centers and countries, cost
data will be summarized by means (and standard devia-
tions) and medians (and interquartile ranges) among all
sites, and by country for all variables, as per our pilot
costing study [9]. Visible outliers will be reconfirmed
with individual hospital contacts before determining
median costs among all centers for each variable in the
dataset to be used for all primary and secondary ana-
lyses. Data from sites that have cost accounting method-
ologies precluding the inclusion of certain data will be
noted, but multi-country median costs will be used to
improve the generalizability of our estimates and to miti-
gate the influence of high and low cost outliers. Prior to
final analyses being undertaken, participating sites will be
re-queried to determine if particular costs have changed
substantially (for example, by more than 25%), beyond
inflationary or deflationary changes, over the course of the
study and if so, the most current costs will be used. Coun-
try and year-specific costs will be converted to US dollars,
first accounting for annual inflation [22-25]. We plan
on using international currency conversion, instead of
purchase power parity (PPP)-based conversions, because
health-specific PPPs are not available for all participating
countries, and non-health PPP conversion rates vary
substantially over the period of the analysis [23]. Country-
specific costs will be considered only in sensitivity ana-
lyses. As of 1 June 2013, 1 United States dollar was worthapproximately 1.03 Canadian dollars, 1.04 Australian dol-
lars, 2.12 Brazilian Real, and 3.75 Saudi Arabian Riyal [23].
E-PROTECT analytic plan
The base case cost-efficacy ratio is the ratio of incremental
costs per incremental effects of LMWH versus unfrac-
tionated heparin during the period of hospitalization.
Incremental costs will be derived for all patients by first
calculating total costs for all patients in each arm of the
PROTECT trial. Item costs will be multiplied by the
frequency or event rates for medications administered,
laboratory and radiological tests incurred, other diagnostic
or therapeutic procedures performed, transfusions received,
per day personnel and ICU or ward costs, depending upon
number of events and length of stay in the ICU and hos-
pital. Total, then median and mean per patient costs for
each of the LMWH and unfractionated heparin groups will
be calculated. Incremental costs will be taken as the differ-
ence in median per patient costs between groups; however,
mean costs will also be provided in order to generate total
costs. Effects for the base case analysis will be calculated
separately for each primary (all thromboses), secondary
(PE, DVT, major bleeding and HIT) and tertiary (survival)
endpoints. Incremental effects will be taken as the differ-
ence in per patient event rates between groups. Therefore
cost-effectiveness ratios will be displayed in terms of incre-
mental costs divided by incremental effects, specifically, the
cost to prevent a thrombosis at any site, the cost to prevent
a PE, DVT, major bleeding event and episode of HIT, and
life-year gained as is commonly used in cost-effectiveness
analysis for VTE prevention strategies (Box 2) [6]. If costs
are less in the LMWH group, a cost-minimization analysis
will be reported, highlighting the difference in costs (with
95% confidence intervals) between groups.
Evaluation Framework Overview
1. Question: Is the use of LMWH as compared to
UFH cost-effective for the prevention of VTE in
critically ill medical-surgical patients?
2. Perspective: Our primary perspective is the acute
healthcare system perspective. We will perform
sensitivity analyses from various geographic regions
participating in the PROTECT trial.
3. Clinical outcomes: Rates of all thromboses, DVT, PE
and complications (for example, bleeding and HIT),
length of stay and mortality (ICU and hospital).
4. Costs: All direct and indirect medical costs
associated with treatment and complications (such
as ICU and non-ICU hospitalization, personnel,
medications, diagnostic testing and procedures)
will be identified and evaluated. Costs will be
converted to Canadian and United States
(2013 dollar rates) costs.
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cost per in-hospital thrombotic event avoided.
Long-term results will be presented in terms of costs
per life year and quality-adjusted life years gained,
using utilities from studies of appropriate duration,
to allow for broad comparison of cost-efficacy with
other medical interventions.
6. Comparators: We will compare LMWH with UFH
for outcomes and associated costs.
7. Time horizon: We will focus on near-term horizons;
costs and incremental cost effectiveness ratio
outcomes at ICU and hospital discharge. We will
model long-term outcomes over a lifetime horizon.
8. Discounting: We will discount cost and utilities at
3% for any longer-term (over one year) analyses.
9. Uncertainty: We will use sensitivity analyses and
bootstrapping to produce confidence intervals.
DVT = deep vein thrombosis; HIT = heparin induced
thrombocytopenia; ICER = incremental cost-effectiveness
ratio; ICU = intensive care unit; LMWH= low molecular
weight heparin; PE = pulmonary embolism; UFH = unfrac-
tionated heparin; VTE = venous thromboembolism.
Outcomes Overview
1. Primary outcome:
Incremental cost per thromboses (any site) avoided
2. Secondary outcomes:
(i.) Incremental cost per PE avoided
(ii.) Incremental cost per DVT avoided
(iii.) Incremental cost per major bleeding event avoided
(iv.) Incremental cost per episode of HIT avoided
3. Tertiary outcomes:
4. Incremental cost per life year and quality-adjusted
life year gained (lifetime horizon)
E-PROTECT subgroups
As subgroup analyses, we will investigate specific patients
in the PROTECT trial who may have differential effects
and costs as compared to the entire population, includ-
ing patients with higher and lower severity of illness
(APACHE1 II score ≥25 versus <25), patients with a
body mass index of ≥40 kg/m2 versus <40 kg/m2, patients
requiring inotropes or vasopressors at enrollment versus
those who do not and medical versus surgical patients.
Although ventilation status was initially planned as a sub-
group, approximately 90% of patients were mechanically
ventilated at enrollment [7] and thus analysis in this sub-
group will not be informative. We will directly calculate
the incremental cost difference and generate 95% confi-
dence intervals using the bias corrected and accelerated
(BCa) method in R, among 1,000 bootstrap samples. Wewill examine the relative influence of all individual costs
using a Tornado diagram.
E-PROTECT sensitivity analyses
As patient characteristics, effects and costs may differ
outside of tightly controlled clinical trials and in various
jurisdictions, we plan a number of sensitivity analyses to
explore how incremental cost-effectiveness ratios may
change with plausible differences in values, including
costs of LMWH and UFH, and per day cost of care in
ICU and hospital wards. We will also perform sensitivity
analyses using the efficacy analysis of the PROTECT
trial that considered only patients who received the
study drug for two days or more and had two or more leg
compression ultrasounds, and by considering only symp-
tomatic thromboses. Multi-way sensitivity analyses will be
performed by varying the estimates of pairs of potentially
influential variables. We will perform a probabilistic sensi-
tivity analysis of pairs of known costs and effects from the
PROTECT trial, using bootstrapping techniques, among
1,000 samples, with replacement, in order to generate an
incremental cost-effectiveness plot [26,27].
Secondary analyses
E-PROTECT post-hospital discharge modeling
Some clinical events may occur after ICU and hospital
discharge and these events may utilize resources (such
as re-admission to the ICU, rehabilitation and physician
visits). Because we cannot follow all patients in the PRO-
TECT trial over their actual life expectancy, we may use
discharge vital statistics and known post-critical illness
follow-up literature to model the lifetime effects and
cost-efficacy ratios of prevention strategies for all patients
in the PROTECT trial, depending upon the results for the
in-hospital time horizon. We will know clinical events and
outcomes until death or discharge from hospital. However,
if the primary analysis implies that long-term effects and
costs are important to explore (particularly if the primary
analysis demonstrates one strategy is more costly but with
greater effects), post-discharge, a Markov-based process
(Figure 1) will be used to model longer-term events and
will allow patients to transition between states of health or
illness until all patients in the model have died [5].
Both background mortality and increased mortality due
to the initial illness, thrombosis event or complication will
be considered. The cycle length will be one month. Tran-
sition probabilities will be taken from the E-PROTECT
follow-up cohort and literature of post-ICU survival. The
E-PROTECT long-term model is informed by the struc-
tures of published models for prophylaxis with LMWH in
other populations [5] and the actual course of the patients
in the PROTECT trial. We will combine these data, and
known utilities of post-ICU discharge states, with out-
comes and life years determined by the PROTECT trial
Figure 1 Markov model for long-term outcomes and costs of critically ill patients in E-PROTECT. See Sud et al. [5]. ICU = intensive care unit;
LMWH= low molecular weight heparin; LTC = long-term care; M =Markov node; UFH = unfractionated heparin; VTE = venous thromboembolism.
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quality-adjusted life years and associated incremental
cost-efficacy ratios. Given our in-hospital primary time
horizon and focus on thrombotic events in the PROTECT
trial, we intentionally will not directly measure short-term
health-related quality of life measurements for our primary
time horizon, but will apply measures of health-related
quality of life for modeled post-hospital survival using data
from longitudinal studies of critically ill patients over an ap-
propriate time horizon [28-36]. We will apply 3% discount-
ing for all effects and costs for any lifetime modeled events.
Statistical analyses
All primary analyses will be based on the intention-to-
treat principle, as per the primary analyses for the PRO-
TECT trial. We use descriptive analyses to describe the
baseline characteristics. Means (and standard deviations)
or medians (and interquartile ranges) will be used to de-
scribe average effect and cost estimates, and Chi-square
tests and two-sample t-test comparisons will be used as
appropriate. We will test for differences in costs using
standard non-parametric tests, and use nonparametric
analysis of variance techniques to test for interactions
with the heparin strategies. For missing or unavailable
data, we will use imputation of the median value from
the appropriate subgroups in E-PROTECT and compare
results obtained with and without imputation to ensure
large variations do not exist [37,38]. Statistical signifi-
cance for differences among a priori comparisons will beset at a P value of 0.05. Primary analysis will be undertaken
using Excel (Microsoft Corp, Redmond Washington,
United States), R (Free Software Foundation) and SAS
(Cary, North Carolina, United States). Post-hospital dis-
charge models will be constructed using Excel and TreeAge
software (TreeAge Software Inc., Williamstown,
Massachusetts, United States).
Ethics
Research ethics approval for E-PROTECT was granted by
Sunnybrook Health Sciences Centre (project identifier:
115-2007). All other sites participating in the economic
evaluation of the PROTECT trial have obtained research
ethics approval for involvement in the PROTECT trial,
or appropriate approval to include non-specific patient-
based costing data (Canada: Queen Elizabeth II Hospital
(Halifax); Hôpital Maisonneuve-Rosemont (Montréal);
Ottawa Hospital (Ottawa); Kingston General Hospital
(Kingston); Mount Sinai Hospital, University Health
Network, St Michael’s Hospital, Sunnybrook Health Sci-
ences Centre (Toronto); St Joseph’s Hospital (Hamilton);
Foothills Hospital (Calgary); University of Alberta Hospital
(Edmonton); St Paul’s Hospital (Vancouver). Australia: Royal
North Shore Hospital (Sydney); Barwon Health (Geelong);
Nepean Hospital (Penrith); Royal Melbourne Hospital,
The Alfred Centre (Melbourne). United States: Rhode
Island Hospital (Providence); Mayo Clinic (Rochester).
Saudi Arabia: King Saud Bin Abdulaziz University for
Health Sciences (Riyadh); King Faisal Specialist Hospital &
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Informed consent was obtained from each participant in
the PROTECT trial, or their substitute decision-maker, in
accordance with local research ethics approvals.
Study oversight
Study operations, methods, submission for funding and
manuscript generation are under the oversight of the
E-PROTECT steering committee (RF, NM, DC, WG,
MG, GG and MK) on behalf of the Canadian Critical
Care Trials Group.
Discussion
The PROTECT trial is the largest trial undertaken of
VTE prophylaxis for critically ill patients. Although
LMWH has been shown to be an effective means of
VTE prophylaxis for many patient populations, it has
historically been associated with a higher drug acquisi-
tion cost than UFH, and the relative effects, side-effects
and broader costs of VTE prophylaxis are unknown. A
prospective economic evaluation is critical to the inter-
pretation of the results of the PROTECT trial. The PRO-
TECT trial results suggest that LMWH may reduce the
frequency of pulmonary embolus and heparin-induced
thrombocytopenia. Thus, physicians, pharmacists and pol-
icy makers will need to know whether the cost provides
good value for the healthcare dollar. An economic evalu-
ation is still critical for alternative clinical outcomes,
particularly for differences in the adverse event profile
between treatments that may lead to additional resource
consumption. E-PROTECT provides an opportunity to
answer these questions and address the cost-efficacy of
VTE prevention using results with minimal risk of bias.
In preparation for E-PROTECT, we have performed a
number of preliminary and sub-studies, including a sys-
tematic review of the VTE economic evaluation literature
to inform cost-drivers, the E-PROTECT pilot study in
three countries to determine feasible and valid cost data
collection, and we have developed a decision-analytic
model to explore both the importance of protocoled
screening versus clinical case finding for VTE, and evalu-
ate the long-term outcomes of various detection and treat-
ment strategies [5,6,9].
Prospective measurement of economic and health out-
come data alongside randomized controlled trials, although
previously rare, has become increasingly common. There
are several advantages [10]. Firstly, the costs of collecting
clinical, economic and long-term follow-up data can be
reduced if they are collected simultaneously. Secondly,
certain data, such as information resource use, are imprac-
tical or impossible to gather retrospectively. Thirdly, the
analysis can take full advantage of randomization to collect
data unlikely to be confounded by differences in baselinecharacteristics between treatment arms. Fourthly, all ele-
ments of the analysis, including decisions regarding model-
ing assumptions and sensitivity analysis parameters and
ranges, can be specified before investigators see unblinded
data, reducing the risk of investigator bias. Finally, the
economic analysis results can be generated at, or only
slightly after, the time that clinical results are available.
Such timely economic data can be particularly useful to
those making budgetary and healthcare resource alloca-
tion decisions, especially if the intervention that is being
evaluated is already in current practice. By conducting our
economic analysis concurrent with the PROTECT trial,
we take advantage of each of these strengths.
The major disadvantage of conducting an economic
analysis concurrently with a randomized clinical trial is
that a randomized clinical trial may not represent the
same effects and costs as routine clinical practice. How-
ever, both the PROTECT and E-PROTECT trials address
this limitation in that we will expose estimates generated
from the PROTECT trial to adjustments in medical and
surgical case-mix and severity of illness, intention-to-treat
and on-treatment estimates, among others. Another po-
tential disadvantage is that the primary outcome of the
PROTECT trial was proximal leg DVT during ICU admis-
sion, confirmed by ultrasound, but which in critically ill
patients is usually asymptomatic. However, the other ven-
ous thrombosis outcomes of the DVT and PE arm were
largely clinically suspected and also objectively confirmed.
There are other aspects of the E-PROTECT trial meth-
odology that deserve consideration. Firstly, our primary
perspective is from the acute healthcare system (not
societal) and our primary time horizon is in-hospital, not
lifetime. This is because patients in the ICU receiving
thromboprophylaxis do not receive it beyond their hos-
pital stay; the intervention is focused on the reduction of
in-hospital VTE events and thus the E-PROTECT trial is
focused upon in-hospital costs. However, we will estimate
post-discharge events and costs using our previously de-
veloped models, should the primary analyses indicate this
to be informative [5].
Secondly, the primary outcome of E-PROTECT is the
incremental cost to avoid a VTE event, not the incremental
cost per life-year gained. This is because the PROTECT
trial is not designed to estimate differences in survival, nor
powered to detect differences in life expectancy; thus, it
would be inappropriate to make this a primary outcome
for E-PROTECT. However, if there were differences in life
expectancy during the PROTECT trial we would address
this as a tertiary outcome. Whereas there are broadly dis-
cussed thresholds of willingness-to-pay for a year of
quality-adjusted life, there are no clear cost thresholds
for VTE event avoidance. To address this, in our system-
atic review of economic evaluations in the VTE litera-
ture, we have summarized the ranges of incremental
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egies. However, if E-PROTECT determines an incremental
cost of LMWH over UFH, we will perform a specific
follow-up study for E-PROTECT that will seek to establish
such a threshold among patients, physicians, pharmacists
and policy makers.
Thirdly, we capture both direct and indirect costs in
E-PROTECT by seeking acute healthcare system line-
item costs as opposed to line-item costs of each patient
enrolled in the PROTECT trial. This stems from our pilot
study demonstrating widely variable institution practices
in reporting patient-specific cost accounting. We will
derive valid direct and indirect costs of care, and avoid
double counting among individual resources used and
institution specific rolled-up patient and overhead costs.
Fourthly, we have chosen to gather costs from acute
healthcare systems in many countries participating in
the PROTECT trial. Although this has the potential to
introduce variability in cost estimates, we believe this
will help our findings be generalizable to more than one
system. We will use international currency conversion
instead of PPP conversions, because health-specific PPPs
are not available for Saudi Arabia, and non-health PPP
conversion rates vary substantially over the period of the
analysis [23]. We will report our findings in a common
currency, using appropriate currency conversion tech-
niques, and adjusted for country specific inflation and
deflation from the date of data acquisition to final
reporting.
Finally, over the course of a five-year clinical trial it is
possible that new data will have emerged to make the
primary trial question less relevant, or that costs for key
variables will have changed. In one recent study, 8,307
patients were randomly assigned to receive enoxaparin
plus elastic stockings with graduated compression, or
placebo plus elastic stockings with graduated compres-
sion [39]. Among all patients, there were similar 30-day
mortality and major bleeding rates. Although important,
there was no ability in the trial to detect actual VTE,
which itself can have important clinical and economic
impact aside from death. Also, although LMWH has his-
torically had a higher drug acquisition cost than UFH,
since the initiation of the PROTECT trial, the drug
acquisition cost for LMWHs has diminished and UFH
has increased [40]. This will be an important consider-
ation for E-PROTECT in order to make the results
contemporary and relevant.
In summary, administration of heparins is a commonly
used strategy for VTE prevention. The PROTECT trial
is important in determining the balance of effects, side
effects and complications associated with LMWH and
UFH thromboprophylaxis in medical-surgical ICU patients.
The PROTECT trial leaves unanswered what consequence
LWMH or UFH use has on the costs of care of patientswith critical illness. E-PROTECT will complement the
PROTECT trial with a pre-specified prospective compre-
hensive economic evaluation. Components of this study
plan could be considered for other economic evaluations in
critical care.
Trial status
The PROTECT trial ClinicalTrials.gov number is NCT0
0182143. At the time of submission, the costing deter-
mination of E-PROTECT has not yet been completed
and subsequent costs and analyses other than those
reported here may be considered and reported, with
justification.
Additional file
Additional file 1: E-PROTECT: The economic evaluation of the
PROTECT (Prophylaxis for ThromboEmbolism in Critical Care Trial)
Study.
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